The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2

Andrey A Ivashchenko; Bogdan A Zagribelnyy; Yan A Ivanenkov; Ilya A Ivashchenko; Ruben N Karapetian; Dmitry V Kravchenko; Nikolay P Savchuk; Elena V Yakubova; Alexandre V Ivachtchenko

doi:10.3390/molecules27154975

The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2

Molecules. 2022 Aug 5;27(15):4975. doi: 10.3390/molecules27154975.

Authors

Andrey A Ivashchenko¹, Bogdan A Zagribelnyy¹, Yan A Ivanenkov¹, Ilya A Ivashchenko¹, Ruben N Karapetian¹, Dmitry V Kravchenko¹, Nikolay P Savchuk², Elena V Yakubova², Alexandre V Ivachtchenko^{1

3}

Affiliations

¹ ChemDiv Inc., San Diego, CA 92130, USA.
² Viriom Inc., San Diego, CA 92130, USA.
³ ASAVI LLC, 1835 E. Hallandale Beach Blvd, #442, Hallandale Beach, FL 33009, USA.

Abstract

The efficacy of aprotinin combinations with selected antiviral-drugs treatment of influenza virus and coronavirus (SARS-CoV-2) infection was studied in mice models of influenza pneumonia and COVID-19. The high efficacy of the combinations in reducing virus titer in lungs and body weight loss and in increasing the survival rate were demonstrated. This preclinical study can be considered a confirmatory step before introducing the combinations into clinical assessment.

Keywords: COVID-19; SARS-CoV-2; antiviral drugs; aprotinin; influenza.

MeSH terms

Animals
Antiviral Agents / pharmacology
Antiviral Agents / therapeutic use
Aprotinin / therapeutic use
COVID-19 Drug Treatment*
Humans
Influenza, Human* / drug therapy
Mice
SARS-CoV-2

Substances

Antiviral Agents
Aprotinin

Grants and funding

This research received no external funding.